Literature DB >> 820230

Mutations in mouse myeloma cells: implications for human multiple myeloma and the production of immunoglobulins.

S Weitzman, D H Margulies, M D Scharff.   

Abstract

Multiple myeloma raises a number of puzzling questions about the production of immunoglobulins and the malignant transformation of lymphoid cells. Some of these questions can be approached by studying mouse plasmacytomas and by genetic and biochemical studies of mouse myeloma cells in culture. The synthesis, assembly, glycosylation, and secretion of immunoglobulin has been analyzed in detail using the mouse myeloma system. The development of a technique that detects variants in clones of cultured mouse myeloma cells has led to the demonstration of a unique genetic instability in these cells. Based on these results a model is presented to explain the high frequency of ligh-chain producing (Bence Jones) myelomas in patients. Finally, mutant cell lines have been recovered which produce defective immunoglobulins similar to those found in heavy-chain disease and some other lymphoproliferative disorders.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 820230     DOI: 10.7326/0003-4819-85-1-110

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  3 in total

1.  [Effect of several chemotherapeutic agents on protein synthesis in leukemic plasma cells (author's transl)].

Authors:  B Emmerich; R Maurer; G Schmidt; J Rastetter
Journal:  Blut       Date:  1979-02-19

2.  Clonal evolution of myeloma cells leads to quantitative changes in immunoglobulin secretion and surface antigen expression.

Authors:  P J Leibson; M R Loken; S Panem; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

3.  Differential regulation of membrane and secretory mu chain synthesis in human beta cell lines. Regulation of membrane mu or secreted mu.

Authors:  L Hendershot; D Levitt
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.